U.S. flag

An official website of the United States government

GTR Home > Tests > Guardant360 Response

Guardant360 Response

  • GTR Test IDHelp: GTR000593444.2
  • Last updated: 2021-08-12
  • Annual Review past due read more
  • Test version history

Clinical testHelp for Solid tumor
Offered by Guardant Health

Overview

Test name

Help

Guardant360 Response

Purpose of the test

Help

This is a clinical test intended for Help: Drug Response, Prognostic, Therapeutic management

Condition

Help

Click Indication tab for more information.

How to order

Help

Licensed physician contacts Guardant Health client services for ordering information.
Order URL Help: https://www.guardanthealth.com/medical-professionals

Specimen source

Cell-free DNA

Methodology

Help
Molecular Genetics
ESequence analysis of select exons
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Other
  • None/not applicable
TTargeted variant analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Other
  • None/not applicable

Summary of what is tested

Click Methodology tab for more information.

Clinical utility

Help

Guidance for management

Citations

Avoidance of invasive testing

Citations

Clinical validity

Help

The clinical validity of Guardant360 Response is supported by over 40 clinical studies in which the Guardant360 assay platform has been used to determine ctDNA changes in baseline and on‐treatment plasma samples. These studies were performed in multiple cancer types (including NSCLC, colorectal cancer, breast cancer, gastric cancer and others), using a variety of therapies (including targeted and immuno‐oncology based therapies and combination regimens with chemotherapy and endocrine therapies). Consistent across all studies is a longer progression free survival and/or overall survival associated with decreasing ctDNA, as molecular response is often observed prior to radiographic evidence.

Citations

Not provided

Testing strategy

Help

An approved physician with a Guardant Health account uses the Guardant sample collection kit to obtain a whole blood sample from the patient. Following Guardant shipping instructions, the sample is sent directly to the laboratory at Guardant Health. A second analysis is performed early on in treatment to assess changes in tumor-derived cell-fee DNA. 000 Licensed physician contacts Guardant Health client services for ordering information.

Test services

Help
  • Liquid biopsy testing for somatic cancer gene variants

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.